164 related articles for article (PubMed ID: 1637074)
1. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Zigmond MJ; Hastings TG; Abercrombie ED
Ann N Y Acad Sci; 1992 May; 648():71-86. PubMed ID: 1637074
[No Abstract] [Full Text] [Related]
2. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
3. Potential of neurotrophic factors in therapy of Parkinson's disease.
Möller JC; Sautter J; Kupsch A
J Neural Transm Suppl; 1996; 48():103-12. PubMed ID: 8988466
[TBL] [Abstract][Full Text] [Related]
4. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Schwarting RK; Huston JP
Prog Neurobiol; 1996 Oct; 50(2-3):275-331. PubMed ID: 8971983
[TBL] [Abstract][Full Text] [Related]
5. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
6. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Xu DL; Yu WC; Pan GB; Chen SD
Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
10. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
11. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
[TBL] [Abstract][Full Text] [Related]
13. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
15. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
16. [Effect of 6-hydroxydopamine on cerebral catecholamines, lipid peroxidation and antioxidant enzymes in rats-concerned with pathogenesis of Parkinson's disease].
Liang L; Jiang D
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Aug; 24(4):223-7, 253. PubMed ID: 1954795
[TBL] [Abstract][Full Text] [Related]
17. Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Funamizu Y; Nishijima H; Ueno T; Ueno S; Mizukami H; Yagihashi S; Tomiyama M
Neurosci Res; 2017 Aug; 121():49-53. PubMed ID: 28392304
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
19. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
[TBL] [Abstract][Full Text] [Related]
20. Levodopa treatment of Parkinson's syndrome: past and future.
Pletscher A
Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
